| Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. | |
| | |
MedLine Citation:
|
PMID: 19423567 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND OBJECTIVES: Anemia and hemoglobin (Hb) variability are associated with mortality in hemodialysis patients who are on erythropoiesis-stimulating agents (ESA). Our aim was to describe the degree of Hb variability present in nondialysis patients with chronic kidney disease (CKD), including those who were not receiving ESA, and to investigate the association between Hb variability and mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Hb variability was determined using 6 mo of "baseline" data between January 1, 2003, and October 31, 2005. A variety of definitions for Hb variability were examined to ensure consistency and robustness. RESULTS: A total of 6165 patients from 22 centers in seven countries were followed for a mean of 34.0 +/- 15.8 mo; 49% were prescribed an ESA. There was increased Hb variability with ESA use; the residual SD of Hb was 4.9 +/- 4.4 g/L in patients who were not receiving an ESA, compared with 6.8 +/- 4.8 g/L. Hb variability was associated with a small but significantly increased risk for death per g/L residual SD, irrespective of ESA use. Multivariate linear regression model explained only 11% of the total variance of Hb variability. CONCLUSIONS: Hb variability is increased in patients who have CKD and are receiving ESA and is associated with an increased risk for death (even in those who are not receiving ESAs). This analysis cannot determine whether Hb variability causally affects mortality. Thus, the concept of targeting Hb variability with specific agents needs to be examined within the context of factors that affect both Hb variability and mortality. |
| | |
Authors:
|
Neil C Boudville; Ognjenka Djurdjev; Iain C Macdougall; Angel L M de Francisco; Gilbert Deray; Anatole Besarab; Paul E Stevens; Rowan G Walker; Pablo Ureña; Pablo Iñigo; Roberto Minutolo; Yosef S Haviv; Karen Yeates; Marisa L Agüera; Jennifer M MacRae; Adeera Levin |
Related Documents
:
|
7234507 - Routine laboratory tests in relation to spleen size and tumour involvement in untreated... 2316507 - Effect of histocompatibility factors on pulmonary retention of indium-111-labeled granu... 2308267 - Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis. 20035217 - Risk factors and outcome of transfusion-related acute lung injury in the critically ill... 1870917 - Sonographic abnormalities of the thyroid gland in longterm survivors of hodgkin disease. 21955537 - Novel positron emission tomography/computed tomography of diffuse parenchymal lung dise... |
Publication Detail:
|
Type: Journal Article Date: 2009-05-07 |
Journal Detail:
|
Title: Clinical journal of the American Society of Nephrology : CJASN Volume: 4 ISSN: 1555-905X ISO Abbreviation: Clin J Am Soc Nephrol Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-07-07 Completed Date: 2009-09-23 Revised Date: 2010-09-27 |
Medline Journal Info:
|
Nlm Unique ID: 101271570 Medline TA: Clin J Am Soc Nephrol Country: United States |
Other Details:
|
Languages: eng Pagination: 1176-82 Citation Subset: IM |
Affiliation:
|
School of Medicine and Pharmacology, University of Western Australia, WA, Australia. neil.boudville@uwa.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Anemia / blood, drug therapy*, mortality* Erythropoietin / therapeutic use* Female Follow-Up Studies Hemoglobins / metabolism* Humans Linear Models Male Middle Aged Multivariate Analysis Predictive Value of Tests Renal Insufficiency, Chronic / blood, mortality* Survival Analysis |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobins; 11096-26-7/Erythropoietin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Early angiography in patients with chronic kidney disease: a collaborative systematic review.
Next Document: Phosphate levels and cardiovascular disease in the general population.